Inactive Instrument

Tetraphase Pharmaceuticals, Inc.

US88165N2045

Tetraphase Pharmaceuticals, Inc. Announces Resignation of David Lubner as Senior Vice President, Chief Financial Officer, Effective January 8, 2016

January 05, 2016 at 02:38 am IST

On January 1, 2016 David Lubner resigned his position as senior vice president, chief financial officer of Tetraphase Pharmaceuticals, Inc. in order to pursue other interests. Mr. Lubner's resignation is effective January 8, 2016.

Latest news about Tetraphase Pharmaceuticals, Inc.

Tetraphase Pharmaceuticals, Inc. Enters into A Termination of Lease and Voluntary Surrender of Premises Agreement	19/20/19	CI
Tetraphase Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2020	14/20/14	CI
La Jolla Pharmaceutical Completes Merger with Tetraphase Pharmaceuticals	31/20/31	CI
Tetraphase Pharmaceuticals, Inc. Announces Executive Changes	29/20/29	CI
Tetraphase Pharmaceuticals, Inc. Announces Resignation of Larry Edwards as CEO	29/20/29	CI
Tetraphase Pharmaceuticals, Inc. Announces Appointment of Michael Hearne as Chief Financial Officer	29/20/29	CI
Tetraphase Pharmaceuticals, Inc.(NasdaqGS:TTPH) dropped from S&P TMI Index	29/20/29	CI
La Jolla Pharmaceutical Company completed the acquisition of Tetraphase Pharmaceuticals, Inc..	28/20/28	CI
Armistice Capital Enters into Support Agreement with La Jolla Pharmaceutical	01/20/01	CI
Tetraphase Pharmaceuticals, Inc.(NasdaqGS:TTPH) dropped from Russell Microcap Value Index	26/20/26	CI
Tetraphase Pharmaceuticals, Inc.(NasdaqGS:TTPH) dropped from Russell Microcap Index	26/20/26	CI
Melinta Therapeutics, Inc. cancelled the acquisition of Tetraphase Pharmaceuticals, Inc..	24/20/24	CI
La Jolla Pharmaceutical Sends Letter to Tetraphase Pharmaceuticals	23/20/23	CI
United States Food and Drug Administration Approves XERAVA of Tetraphase Pharmaceuticals, Inc	05/20/05	CI
AcelRx Pharmaceuticals, Inc. cancelled the acquisition of Tetraphase Pharmaceuticals, Inc..	04/20/04	CI
Melinta Therapeutics, Inc. made a proposal to acquire Tetraphase Pharmaceuticals, Inc. for $13.1 million.	15/20/15	CI
Tetraphase Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	08/20/08	CI
La Jolla Pharmaceutical Company made a non-binding proposal to acquire Tetraphase Pharmaceuticals, Inc. for $14.6 million.	06/20/06	CI
AcelRx Pharmaceuticals, Inc. definitive merger agreement to acquire Tetraphase Pharmaceuticals, Inc. for $10.4 million.	16/20/16	CI
Tetraphase Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	12/20/12	CI
Tetraphase Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	12/20/12	CI
Tetraphase Pharmaceuticals, Inc. announced that it has received $9.997939 million in funding from Armistice Capital LLC	28/20/28	CI
Tetraphase Pharmaceuticals, Inc. Announces Director Appointments	23/20/23	CI
Tetraphase Pharmaceuticals, Inc. announced that it expects to receive $9.997939 million in funding from Armistice Capital LLC	22/20/22	CI
Tetraphase Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	13/19/13	CI

Chart Tetraphase Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections. The Company also develops TP-6076 for multidrug-resistant gram-negative infections. Eravacycline is a fluorocycline antibiotic. The Company is conducting a global Phase III clinical program for eravacycline called Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE). TP-271 is a fully synthetic fluorocycline being developed for respiratory disease caused by bacterial biothreat pathogens in healthy volunteers.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+38.51%	727B
NOVO NORDISK A/S	+33.05%	599B
JOHNSON & JOHNSON	-6.23%	354B
MERCK & CO., INC.	+18.78%	328B
ABBVIE INC.	+1.35%	277B
ASTRAZENECA PLC	+16.00%	243B
NOVARTIS AG	+8.09%	205B
ROCHE HOLDING AG	-5.77%	203B
AMGEN INC.	+6.19%	164B

Other Pharmaceuticals